Related Experiment Video
Updated: Apr 2, 2026

Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis
Published on: January 16, 2013
Vitamin E alleviates experimental autoimmune prostatitis by inhibiting the EGFR/MAPK pathway to reduce M1 macrophage
Yifan Zhang1, Shun Xu1, Cheng Zhang1
1Department of Urology, the First AffiliatedHospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, China; Institute of Urology, Anhui Medical University, Hefei, Anhui, China; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, Anhui, China.
Abstract:
A major urological condition that manifests in the form of urinary abnormalities, pelvic region pain, and sexual problems is known as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The underlying pathogenesis of this disorder remains poorly understood.. The effects of vitamin E (VitE) on mitigating CP/CPPS were investigated here. In individuals with CP/CPPS, serum pro-inflammatory factors were found to be significantly increased. A mouse model of experimental autoimmune prostatitis (EAP) and RAW264.7 mouse macrophages were used to evaluate the effects of VitE. The results showed that VitE administration significantly and dose-dependently ameliorated prostatic inflammatory infiltration and pain in EAP mice, and decreased the serum levels of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Similar reductions were observed in the culture supernatants of RAW264.7 cells. Mechanistic studies revealed that VitE potently suppressed macrophage M1 polarization by downregulating epidermal growth factor receptor (EGFR) and decreasing phosphorylation of its downstream mitogen-activated protein kinase (MAPK) pathway components. Treatment with the EGFR agonist NSC228155 or overexpression of EGFR in cells counteracted the effects of VitE, reversing its anti-inflammatory effects and promoting M1 polarization. Molecular docking and surface plasmon resonance (SPR) analyses confirmed direct binding between VitE and EGFR. In summary, this study reveals that VitE alleviates CP/CPPS at least in part by inhibiting the EGFR/MAPK axis, thereby reducing M1 macrophage polarization. These findings provide a theoretical foundation for the potential use of VitE in CP/CPPS treatment.
Insights
Vitamin E (VitE) effectively reduces inflammation and pain in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) by inhibiting the EGFR/MAPK pathway and decreasing M1 macrophage polarization.
Area of Science:
- Urology
- Immunology
- Pharmacology
Background:
- Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common urological condition with poorly understood pathogenesis.
- Elevated pro-inflammatory factors are observed in patients with CP/CPPS.
Purpose of the Study:
- To investigate the therapeutic effects of vitamin E (VitE) on CP/CPPS.
- To elucidate the underlying molecular mechanisms of VitE's action.
Main Methods:
- Utilized a mouse model of experimental autoimmune prostatitis (EAP) and RAW264.7 macrophages.
- Assessed inflammatory markers, pain, and macrophage polarization.
- Investigated the role of the epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase (MAPK) pathway.
- Performed molecular docking and surface plasmon resonance (SPR) analyses.
Main Results:
- VitE administration significantly ameliorated prostatic inflammation and pain in EAP mice.
- VitE dose-dependently decreased pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) in vivo and in vitro.
- VitE suppressed M1 macrophage polarization by downregulating EGFR and inhibiting the MAPK pathway.
- Direct binding between VitE and EGFR was confirmed.
Conclusions:
- Vitamin E alleviates CP/CPPS symptoms by inhibiting the EGFR/MAPK signaling pathway.
- VitE reduces inflammation through the suppression of M1 macrophage polarization.
- These findings support the potential of VitE as a therapeutic agent for CP/CPPS.
More Related Videos
06:19Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
06:57Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
Published on: May 12, 2023